RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)

Trial Details

NCT ID
NCT05765500
Phase
PHASE2
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Relugolix
  • Leuprolide
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Foxborough, Massachusetts, United States|42.06538,-71.24783

Key Eligibility Criteria

  • Participants must have a histologic diagnosis of prostate adenocarcinoma.
  • Participants must be eligible for treatment with 6 months of ADT with leuprolide depot or relugolix without additional systemic therapies other tha…
  • Participants cannot have received prior GnRH agonist or antagonist therapy.
  • Patients must have testosterone level \> 200 ng/mL prior to initiation of ADT.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →